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The article examines the role and challenges of scientiﬁc self-governance and standardization in inter-
continental clinical research partnerships in stem cell medicine. The paper shows that e due to a high
level of regulatory diversity e the enactment of internationally recognized standards in multi-country
stem cell trials is a complex and highly situation-speciﬁc achievement. Standardization is imposed on
a background of regulatory, institutional and epistemic-cultural heterogeneity, and implemented
exclusively in the context of select clinical projects. Based on ethnographic data from the ﬁrst trans-
continental clinical trial infrastructure in stem cell medicine between China and the USA, the article
demonstrates that locally evolved and international forms of experimental clinical research practices
often co-exist in the same medical institutions. Researchers switch back and forth between these
schemas, depending on the purposes of their research, the partners they work with, the geographic scale
of research projects, and the contrasting demands for regulatory review, that result from these differ-
ences. Drawing on Birch's analysis of the role of standardization in international forms of capital pro-
duction in the biosciences, the article argues that the integration of local knowledge institutions into the
global bioeconomy does not necessarily result in the shutting down of localized forms of value pro-
duction. In emerging ﬁelds of medical research, that are regulated in highly divergent ways across
geographical regions, the coexistence of distinct modes of clinical translation allows also for the pro-
duction of multiple forms of economic value, at varying spatial scales. This is especially so in countries
with lenient regulations. As this paper shows, the long-standing absence of a regulatory framework for
clinical stem cell applications in China, permits the situation-speciﬁc adoption of internationally
recognized standards in some contexts, while enabling the continuation of localized forms of value
production in others.
© 2014 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
In this article, I focus on processes of scientiﬁc self-governance
and standardization in the context of intercontinental clinical
research collaborations in the ﬁeld of regenerative stem cell med-
icine. I will explore, furthermore, the implications of these pro-
cesses on local clinical innovation practices, and the production of
localized forms of economic value. The paper explores these issues
by focusing on the formation of the China Spinal Cord Injury
Network (China SCI Net), the ﬁrst intercontinental clinical trials
infrastructure in the stem cell ﬁeld that has emerged betweenmann@hotmail.com.
Ltd. This is an open access articlemedical researchers in mainland China, Hong Kong, Taiwan and the
USA.
The emergence of a global clinical trial landscape has been a key
theme in the literature on industry-sponsored forms of clinical
research on vaccines and drugs based on chemical compounds
(Leach et al., 1999; Gikonyo et al., 2008; Petryna, 2009; Sariola and
Simpson, 2011). To date, however, no study has systematically
focused on the formation of international clinical trials in the ﬁeld of
regenerative stem cell medicine. Existing academic work on the
clinical translation of stem cell-based therapeutic approaches has
focused either on processes of preclinical development (Cribb et al.,
2008; Martin et al., 2008; Wainwright et al., 2006), or on clinical
research in the context of national jurisdictions, especially in theUSA
and in countries of the European Union (Wilson-Kovacs et al., 2010;
Webster et al., 2011). A third body of work has been concerned withunder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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cells, outside of themethodological format of the clinical trial. These
studies have commented in particular on the situation in China
(Song, 2011; Chen and Gottweis, 2013; Rosemann, 2013a) and India
(Bharadwaj, 2013; Sleeboom-Faulkner and Patra, 2011).
The development of regenerative stem cell medicine through
internationally acknowledged multi-country clinical trial partner-
ships has remained unexplored so far. This is an important
analytical shortcoming. A focus on the formation of international
clinical trial infrastructures provides important opportunities to
gain insights into the processes and challenges involved in the
development, organization, and governance of large-scale, trans-
continental clinical research collaborations in the ﬁeld of regener-
ative stem cell medicine (as well as other emerging ﬁelds of
medicine research). Of particular interest, in this respect, are pro-
cesses of standardization, which in recent years have evolved as
important concerns in the social study of medicine research
(Timmermans and Berg, 1997; Timmermans and Epstein, 2010;
Birch, 2012). The evolving ﬁeld of clinical stem cell medicine
forms an interesting case in this respect. In contrast to established
forms of drug research, for clinical stem cell research there are as
yet no internationally binding standards or harmonized global
governance frameworks, and widely divergent regulatory condi-
tions exist across (and within) countries. The governments of the
USA, the European Union and some other countries have now
developed legal arrangements for the licensing of stem cell-based
medicinal products (Halme and Kessler, 2006; Faulkner, 2012). In
many other countries, however, including in population rich
countries such as China and India e where unproven for-proﬁt
applications with stem cells constitute a huge market e the
development of regulatory frameworks is evolving only gradually
(Sleeboom-Faulkner and Patra, 2011; Rosemann, 2013a). In China,
the experimental clinical use of stem cells remained completely
unregulated until January 2012, with the result that highly dis-
similar types of clinical research and experimental for-proﬁt ap-
plications have surfaced since the early 2000s (Chen, 2009; Song,
2011; Rosemann, 2013a).
The argument in this paper is developed in two parts. First, I will
show that the high level of regulatory diversity in the international
landscape of clinical stem cell research, poses a signiﬁcant challenge
to the organization of cross-continental clinical trial collaborations.
By focusing on the formation of the China Spinal Cord Injury
Network (China SCI Net), the ﬁrst trans-continental clinical trial
infrastructure in stemcellmedicine between China and theUSA, the
article will elucidate that the enactment of internationally recog-
nized clinical research standards is a complex and highly situation-
speciﬁc achievement. Standardization, as will be shown, relies on
extensive forms of scientiﬁc self-governance, and requires far-
reaching adjustments of local clinical research environments.
Internationally approved methodological protocols are established
against a background of regulatory, institutional and epistemic-
cultural heterogeneity, and implemented in the situational context
of the clinical trials organized by the China SCI Net. Exterior to the
activities of the China SCI Net, we see that locally evolved and newly
adopted (i.e. internationally accepted) forms of experimental clin-
ical research practices exist side by sidewith each other, often in the
same medical institutions. Researchers shift between these diver-
gent schemas, depending on the purposes of their research, the
partners they work with, the geographic scale of research projects,
and the contrasting demands for regulatory review, that result from
these differences. Second, based on these insights I will engage in a
dialogue with a recent analysis of the role of standardization in the
creation of value in the biosciences by sociologist Kean Birch (2012).
I will argue that e in the regenerative medicine ﬁeld e the inte-
gration of local knowledge institutions into the global bioeconomydoes notnecessarily result in the shuttingdownof localized formsof
value production. While the blocking of local forms of capital pro-
duction in the biomedical sciences can be observed in particular in
established ﬁelds of medical research, and in countries with strin-
gent regulatory controls in place, in emerging ﬁelds of medicine
research, a more diversiﬁed situation exists. In emerging socio-
technical ﬁelds of medical research, such as regenerative stem cell
medicine, which is regulated in highly divergent ways across (and
often within) geographical regions, the close proximity between
locally evolved and internationally recognized forms of clinical
translation allows also for the production of multiple forms of eco-
nomic and scientiﬁc value. Localized forms of value creation in
medical institutions, that do not conform to the requirements of
international scientiﬁc standard regimens, continue to existe aside
to participation in internationally approved, multi-country clinical
research projects. Geographic location, and regulatory differences
between these locations, is a key factor in explaining this situation.
As this paper shows, the long-standing absence of a comprehensive
regulatory framework for clinical stem cell applications in China
permits the situation-speciﬁc adoption of internationally recog-
nized standards in some contexts, while enabling the continuation
of local forms of value production in others.
2. Empirical context and methodology
The empirical focal point of this article is an ethnographic study
of the China Spinal Cord Injury Network (China SCI Net), an aca-
demic clinical trials infrastructure that involves more than twenty
spinal cord injury (SCI) centers in mainland China, Hong Kong, and
Taiwan. The Network is registered as a non-proﬁt corporation in
Hong Kong, and was founded in 2005 by Professor Wise Young
from Rutgers University in New Jersey, in close collaboration with
leading researchers from Hong Kong and the Chinese mainland
(Rosemann, 2013b). Since 2009, the China SCI Net has been paral-
leled by the Spinal Cord Injury Network USA (SCI Net USA), which
comprises eight academic hospitals. The aim of this evolving
transnational research economy is to develop and clinically assess
stem cell-based combination therapies for spinal cord injury, and
the licensing of successfully tested treatments in China, Hong Kong,
Taiwan, the USA, and potentially other countries in the world. Until
April 2014, the China SCI Net had conducted seven clinical studies.
An initial noninterventional observational study was carried out
between 2005 and 2008 in twenty-two hospitals to collect diag-
nostic and long-term follow-up data from up to 600 acute and
chronic SCI patients. This study was followed by ﬁve phase I and II
trials that have been conducted in chronic SCI patients, in two
university hospitals in Hong Kong and one military hospital in
China. Two of these studies tested the safety and efﬁcacy of lithium
in SCI patients, and three studies an experimental combination
therapy of umbilical cord blood (UCB) mononuclear cells, lithium,
and methylprednisolone. A Phase III trial incorporating more hos-
pitals (including those in Taiwan) is being planned in 2014. The SCI
Net USA has not yet conducted clinical trials, but Phase II and Phase
III studies are in preparation. The UCB stem cells that are used in the
trials of the Network are sponsored by the US-Taiwanese umbilical
cord blood bank company Stemcyte. The organization of the trials
itself is covered by ﬁnancial resources raised within China and
Hong Kong (Rosemann, 2013b).
The data presented in this article have been gathered during a
period of ten months of ethnographic ﬁeldwork in Hong Kong,
Taiwan, and mainland China, between April 2010 and April 2011.
The formation of the China SCI Net was analyzed against the wider
background of clinical stem cell research and applications in these
regions, particularly in mainland China (Rosemann, 2011, 2013a).
The data generated in Taiwan are not included in this article
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stage took place in Hong Kong and China.
Several methods of data collection were employed during the
research process. Open-ended, in-depth interviews were conduct-
ed with twenty-eight people afﬁliated to the China SCI Net. These
included senior executives, principal investigators, clinical re-
searchers, and fundraisers, from ten participating hospitals and
institutes. These interviews were either tape-recorded and tran-
scribed verbatim, or recorded by hand during the interview pro-
cess. All interviewees were explained the purposes of the research,
and verbal consent to use interview data for academic publications
was obtained. Documentary research was conducted using text
sources provided by people from the Network and from the
Internet. These documentary sources included scientiﬁc papers,
opinion pieces, newspaper articles, blog contributions of re-
searchers, as well as video-documentation of panel discussions and
presentations during international symposia organized by the
China SCI Net. The article draws, furthermore, on observations of
scientiﬁc conferences, expert meetings, and visits to hospitals and
research centers. The research that underlies this article has
received ethical review and approval by the University of Sussex.
Data analysis was ongoing during ﬁeldwork and in the months
thereafter. Everyday work practices and organizational procedures
were examined in relation to the institutional and regulatoryorders,
in whose context these activities took place (Smith, 2005). By
repeatedly reading and coding interview transcripts, ﬁeld notes and
relevant text sources I identiﬁed, in a ﬁrst step, the different stages
and procedures through which standardized research protocols
were developed and implemented in the context of the China SCI
Net. Then, in a second step I explored the challenges to standardi-
zation, and theways inwhich these difﬁcultieswere interpreted and
tried to be solved. This second line of analysis was based on the
constant comparative method (Boeije, 2002) and triangulation of
data from different sources. In a third step I examined the similar-
ities and differences between locally evolved and internationally-
recognized experimental clinical practices in hospitals that take
part in international stem cell trials. In order to discern the speciﬁc
forms of value creation that emerged from these distinct experi-
mental practices, I relied on the investigation of interview data and
the analysis of hospitalwebsites, commentaryandopinionpieces, as
well as advertising materials from the Internet.3. Intercontinental stem cell trials and the role of scientiﬁc
self-governance
What we are trying to do is to bring the international standards
of clinical trials to China. [W]hat we are doing is to bring in the
concept of using all the modern standards on how to run a
clinical [stem cell] trial, as it is recognized in the West, in the
current time. All the conceptions of leading this network …
evolve around that concept. […] First of all we had to promote
the interest […] to bring in experts from around mainland
China, Hong Kong, Taiwan […], to provide a platform. And the
second level is, wewould then bring in the knowledge as to how
a clinical trial should be run, in an internationally recognized
manner.
(Prof Kwok-Fai So, Co-Director of China SCI Net)1
Multicountry clinical trial collaborations, such as the China SCI
Net, represent the ﬁrst projects in regenerative stem cell medicine1 Interview Kwok-Fai So, Hong Kong, January 7, 2011.where such processes of cross-border standardization can be
observed.
Standards, as Brunsson and Jakobsson have pointed out, coor-
dinate assemblages of things and people into new conﬁgurations,
and in doing so transform existing practices, institutional ar-
rangements, and related social orders (2000: 49). In the case of the
China SCI Net this reconﬁguration of things, practices, arrange-
ments, and people is based on an interconnected sequence of
organizational procedures, educational, and training activities, and
the employment of a tailor-mademonitoring and control system. In
the absence of a harmonized global governance framework for
clinical stem cell research, these efforts rest primarily on extensive
forms of transnational scientiﬁc self-governance. Such project-
internal forms of self-governance are strategic efforts to navigate
through a diverse and internationally nonharmonized regulatory
environment; the aim is to create compliance with the divergent
requirements of drug regulatory authorities and related processes
of peer review in multiple countries (cf. Wahlberg, et al., 2013). A
focus on these processes of scientiﬁc self-governance, provides
important insights into the ways in which scientists try to balance
out regulatory disparities between regions and institutions,
compensating for regulatory gaps, and creating congruence with
the auditing demands of diverging regulatory and political systems
(Sariola and Simpson, 2011; Sleeboom-Faulkner, 2013).
Indeed, if data from clinical trials that are conducted in one
country are to be used for investigational new drug applications in
other countries (as in case of the China SCI Net, where data from
Phase I/II trials conducted in Hong Kong and mainland China are to
be used to obtain approval for Phase II and III trials in the USA,
Taiwan, and Hong Kong), the basic regulatory requirements of these
countries' drug regulatory authorities must be met. Clinical trials
conducted by the Network in mainland China thus must be
congruent with the methodological standards required for the
approval of later-stage (or parallel) trials, by the health authorities
in Hong Kong, Taiwan, and the USA. I will now turn to the ways in
which such transnational forms of scientiﬁc self-governance are
enacted, and how standardization across involved institutions is
achieved. Three central aspects shall be highlighted in this respect:
selection, restructuring, and the forestalling of regulatory gaps.
3.1. Selection
Selection of the hospitals destined to take part in the Network's
clinical trials is an ongoing process. This means that only some of
the twenty-ﬁve hospitals that initially agreed to join the China SCI
Net will ultimately participate in the organization's clinical trials.
Selection depends, in essence, on the ability of afﬁliated centers to
provide evidence that the standards and criteria required for
participation in internationally recognized (multicenter) clinical
trials can be met. A combination of external and internal assess-
ment parameters is handled in this respect. External assessment
parameters refer to outward qualiﬁcation criteria of associated
hospitals. These include the Chinese good clinical practice (GCP)
certiﬁcation (i.e., the recognition of hospitals as certiﬁed clinical
trial units, following a qualiﬁcation procedure under the National
Health and Family Planning Commission [NHFPC; the former
Ministry of Health]).2 They include, furthermore, the availability of
good laboratory practice (GLP) accredited laboratory facilities.3
Internal assessment parameters refer to criteria that are imposed
on afﬁliated hospitals by the Network itself. These internal quali-
ﬁcation criteria can be divided into “performance-based” and2 Interview Wise Young, Hong Kong, June 24, 2010.
3 Interview Kent Tsang, Hong Kong, January 7, 2011.
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such as checks of hospital internal institutional review board (IRB)
approval procedures, the availability of the necessary technical
instruments, adequate specialist staff, sufﬁcient hospital beds, in-
surance protection for patients, and adherence to other technical
and clinical conditions that are contractually deﬁned between the
China SCI Net's headquarter and afﬁliated hospitals. Performance-
based assessment criteria have been exerted ﬁrst in the context
of the Network's observational clinical study that was conducted in
twenty-two hospitals between 2005 and 2008, but have been
applied in all further trials that the organization has conducted
since then. Performance-based criteria focus, above all, on the
compliance (of each participating hospital) to a clinical trial's pro-
tocol, which prescribes the exact clinical, methodological, technical,
and organizational procedures of a study. The monitoring of pro-
tocol compliance involves the observation of the correct handling
of inclusion and exclusion criteria, the conduct of physiological
examinations and follow-up investigations, the accurate comple-
tion of data sheets, and informed consent procedures. These
monitoring tasks are done from the Network's headquarters in
Hong Kong, which is staffed by the organization's Vice-President
Dr. Wendy Cheng, as well as a full-time GCP monitor, and a
biostatistician. The headquarters operates under the supervision of
the Network's board of directors. The Hong Kong ofﬁce is the nerve
center of the China SCI Net. All operations of the organization, as
well as communication with afﬁliated hospitals, are coordinated
from here. In addition to arranging the logistics of the Network's
clinical trials, and the monitoring of the activities and performance
of participating hospitals, the headquarters also plays a central role
in the restructuring of institutional arrangements and practices in
associated centers.
3.2. Restructuring
The formation of a standardized multi-enter clinical trial infra-
structure that operates according to internationally recognized
principles requires signiﬁcant adjustments of local clinical research
practices and conditions in Network-afﬁliated hospitals. These
changes were achieved by an intensive training program and the
implementation of performance-based assessment procedures,
through which required institutional adjustments could be moni-
tored, anddif necessarydcorrected. Training for staff members of
the relevant departments in the twenty-ﬁve associated research
hospitals began in 2005, with three to four meetings per year until
2009. A ﬁrst target was the standardization of neurological exam-
ination procedures to ensure valid and replicable assessment of the
injury grade of spinal cord injury patients on the trial.
When we ﬁrst came here, the neurological assessment of spinal
cord injury e almost everywhere e was completely haphazard.
It ranged from, eh, you know… you take a pin, you put it here,
you touch a patient, ask “Can you feel it?” There was no disci-
pline … no common languages, no common neurological
assessment of the patients.4
Standardization of neurological assessment was the ﬁrst in a
long list of methodological, clinical, and organizational issues that
were addressed. Training addressed aspects of clinical trial design,
such as protocol development, quality assurance measures, the
reliable use of outcome measures, long-term follow-up of patients,
and the ethical and legal issues of clinical trials, as well as re-
quirements by foreign drug regulatory authorities and4 Interview Wise Young, Hong Kong, June 24, 2010.international journals. In its training program, the China SCI Net did
not work with an examination system. Instead, new contents and
practices were transmitted through demonstrations and educa-
tional materials, and compliance to newly introduced standards,
protocols, and standardized procedures was then tested in practice.
A crucial endeavor in this respect was the organization of the
observational (i.e., non-interventional) trial CN100, a multicenter
study that was conducted in twenty-two hospitals in mainland
China, Hong Kong, and Taiwan. The purpose of this study was to
collect long-term data from 600 chronic and acute spinal cord
injury patients, in accordance with international recruitment and
measurement protocols. In addition to the scientiﬁc value of this
studydwhich was the ﬁrst longitudinal observational study of
chronic and acute spinal cord injury patients in Chinadit fulﬁlled a
central function for the Network: to serve as a test trial of the ability
of afﬁliated centers to recruit patients, to conduct standardized
neurological assessments [based on the ASIA scheme, developed by
the ISCS], to carry out long-term follow-ups, and to document data
and data-collection procedures in the prescribedd-
standardizeddfashion. This study helped in identifying various
challenges:
The ﬁrst trial we held was an observational trial. To show that
the hospitals can deliver the data … Now this study revealed a
lot of problems I actually had heard about, but never really
encountered, until to this point. The number one problem in
China is really to get patients to come back [for follow-up in-
vestigations].… But we [also] observed data that just could not
have been. You knowe patient datawould be the same, over the
whole year period. Suggesting that someone had examined the
patients very carefully… It became very clear to us that we need
to have very good controls of the protocol.5
Due to these problems, instead of the intended 600 patients
only 386 patient proﬁles were completed in this ﬁrstdentirely
observationaldstudy. These insights into local conditions and
related challenges resulted in the wide-ranging restructuring of the
control and monitoring structures through which the Network
operated, such as the introduction of a supervisoreprincipal
investigator double-signing system. With this system, each doctor
or nurse involved in examination of patients has to “sign off” the
data collection sheet with his or her supervisor and the principal
investigator in the institute. Documentation protocols, moreover,
were changed from paper to a computerized web-based system for
data entry, in order to enhance data insertion and data analysis, and
to permit continuous checks by the headquarters in Hong Kong.
Identiﬁcation of challenges in this observational study gave rise,
too, to adjustments of training procedures, as well as the decision to
work with a Contract Research Organization (CRO) during the
forthcoming Phase III trial.6
3.3. The forestalling of regulatory gaps
The selection of suitable hospitals, and adjustments of local
clinical research practices and conditions, aim at the consistent
implementation of fully standardized clinical research protocols. In
contrast to multicenter clinical trials that are conducted in a single
country, the project-internal forms of self-regulation, capacity
building, and institutional restructuration that have been described
constitute a long-term strategic endeavor to create congruence
with the auditing demands of widely varying regulatory and legal5 Same source as in note iv.
6 Same source as in note iv.
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had been approved exclusively by the regulatory authorities in
Hong Kong and mainland China, but the data from these trials will
be used for investigational new drug applications (INDs) in the USA.
This required an enduring anticipatory engagement with the re-
view and approval criteria of the US Food and Drug Administration
(FDA) with respect to the “acceptance of foreign clinical studies not
conducted under an investigational new drug application (non-IND
foreign clinical studies)” (Federal Register, 2008). This constant
need for forms of “anticipatory audit” (Strathern, 2000: 308) re-
quires the identiﬁcation and forestalling of regulatory gaps be-
tween national jurisdictions from an early stage of the clinical
translation process. A brief example will serve to illustrate this
point. At the time of writing, the Health Department of the Army
General Logistics Department in China (the regulatory agency that
approved the China SCI Net's clinical studies in mainland China) did
notmandatorily require that clinical studies should be conducted in
compliance with ICH-GCP standards. Nor did it require the clinical
trials to be conducted exclusively in hospitals certiﬁed by the Chi-
nese MOH, as ofﬁcially recognized clinical trial units. However, the
US FDA's list of requirements for the acceptance of “non-IND
foreign trials” (in the context of IND applications at the US FDA)
states that “accordance with good clinical practice (GCP), including
review and approval by an independent ethics committee (IEC)” is
obligatory (Federal Register, 2008). In order to preempt any difﬁ-
culty arising from these discrepancies, the China SCI Net tried to
forestall regulatory gaps from the outset, and ensured their clinical
trial protocols were fully GCP compliant and only MOH-certiﬁed
hospitals were selected. Moreover, in addition to approval by the
Army General Logistics Department in Beijing, ethics committee
review was also sought by Western IRB, a for-proﬁt IRB in the USA
with close ties to the US FDA.
4. The emergence of new style of practice
In their analysis of the development of cancer clinical trials in
the USA, Keating and Cambrosio described this process as the
establishment of a “new style of biomedical practice” (2011: 3). This
new style of practice encompassed the organization of clinical trials
within a cooperative group system, and the development of most of
the now commonly used methodological components of multi-
center clinical trials. The work in cooperative groups evolved
gradually since the mid-1950s, on the initiative of the U.S. National
Cancer Institute (NCI). Specializing in speciﬁc forms of cancer, these
groups involved hospitals, academic centers, and government de-
partments, and constituted steady platforms for the design of new
research and the conduct of clinical trials (2011: 86). These coop-
erative oncology groups soon expanded into national-level orga-
nizations with their own centralized institutions that were
responsible for the coordination of all successive steps of the clin-
ical translation process. In this system, decisions regarding the
design of clinical trial protocols and the organization, execution,
approval and statistical data analysis of clinical trials were no
longer taken by individual investigators, but in a collectivist process
by the cooperative's committees and its centralized administra-
tional units (2011: 25e6).
In the China SCI Net we see processes of collectivization and
standardization emerging that in several respects are similar to the
cooperative clinical trial system described by Keating and Cam-
brosio. In the mid-2000s, at the time the China SCI Net was
launched, the organization of an academia-based multicenter
clinical trial infrastructure was still a radical novelty in the stem cell
ﬁeld in China. While standardized multicenter drug trials had been
conducted in China by multinational pharmaceutical companies
since the early 1990s (Cooper, 2008), clinical experimentationswith stem cells were for many years based largely on an “the-art-
of-medicine” approach, in which tailor-made experimental treat-
ments were designed for the idiosyncratic needs and disease con-
ditions of individual patients (Rosemann, 2013a). Against this
background, the formation of an internationally operating multi-
center clinical trial infrastructure that would allow for the testing
and marketization of stem cell-based medicinal products, not only
in mainland China, but also in Hong Kong, Taiwan, and at a later
point in the USA, was a radical and fundamentally new concept.
Similar to the cooperative oncology research groups described
by Keating and Cambrosio, the China SCI Net established a
centralized administrative structure, in which the monitoring of
clinical and data collection procedures, statistical analysis, and
decisions regarding protocol development and the selection of
candidate therapies for future clinical trials were collectivized.
These tasks were performed by specialist staff in Hong Kong, and by
expert committees that comprised researchers from afﬁliated in-
stitutions and independent experts, from mainland China, Hong
Kong and the USA. Together with the installing of a standardized
research methodology that is suitable for the conduct of multi-
center clinical trials, these changes have established a new style of
clinical research practice in Network-afﬁliated hospitals that is
based on extensive adjustments of local research procedures. As
with the cooperative oncology groups in the USA, the China SCI Net
functions as an “epistemic organization” in which clinical trials are
not isolated events, but elements of an “integrated, open ended set
of activities that stretch back and force in time” (Keating and
Cambrosio, 2011: 24). The design of new trials is built on previ-
ous trials, and the use of standardized methodological protocols
allow for systematic comparison andmeta-reviews of ﬁndings from
multiple studies over time.
A fundamental difference with the cooperative group system
described by Cambrosio and Keating is, however, that afﬁliated
investigators of the China SCI Net are entirely free to conduct their
own clinical studies, exterior to the organizational framework of
the Network. A central reason for this is, of course, that the China
SCI Net is an independent research groups that is neither a
national-level organization nor structured around a government
research institution (such as the NCI, which is at the center of the
cooperative oncology group system in the USA). Thus, in contrast to
the cooperative groups in the USA, where members are prevented
from initiating investigator-initiated collaborations outside of the
cooperative system, researchers from the China SCI Net can inde-
pendently pursue their own projects. Membership is solely
delimited to participation in the trials that the Network organizes.
It does not impinge on, or restrict, any other activities that
Network-afﬁliated investigators conduct in their own departments
or institutions.
Indeed, as I will now show, exterior to the institutional frame-
work of the China SCI Net a stream of highly divergent forms of
clinical experimentation has been employed in recent years. In a
hospital in North China, for example, a doctor had offered experi-
mental for-proﬁt therapies with olfactory ensheathing cells in
hundreds of SCI patients. In other hospitals I visited, various non-
controlled clinical pilot studies with stem cells were conducted,
but none of these studies could be published in international
journals because the methodology of these studies was described
as insufﬁcient (Young, 2008). In a clinic in South China, on the other
hand, participation in rigorous RCTs (as part of the activities of the
China SCI Net) coexisted with the conduct of less systematic clinical
studies, in which experimental treatments with various cell types,
and other experimental treatment approaches, were offered to
patients, on a pay-to-participate schema. Apparently, these studies
did not entirely conform to international EBM clinical research
standards. Attempts to publish results from these studies in
A. Rosemann / Social Science & Medicine 122 (2014) 72e80 77internationally recognized academic journals repeatedly failed
(Young, 2008).
However, in the context of my interviews with clinical re-
searchers afﬁliated to the China SCI Net, it became clear, that a shift
toward the employment of more systematic clinical studies was
gradually taking shape in Network-afﬁliated hospitals. Most of the
Principal Investigators with whom I spoke mentioned plans for
trials with the use of control groups, and more rigidly handled in-
clusion criteria.7 One of the hospitals I visited was in the process of
planning a larger Phase III trial and had set up a province-level
multicenter clinical network to this end.8 These changes can, with
high likelihood, be related to the extensive training and education
program introduced by the China SCI Net.
5. Standardization as situation-speciﬁc achievement
Standards, as pointed out by sociologists Timmermans and
Epstein, construct a state of stability and order across diversity and
plural possibilities (2010: 71). As underlying scripts of rules, pro-
cedures and values, standards produce uniformities in behavioral
practices, sociotechnical arrangements and knowledge
(Timmermans and Berg, 1997). For international scientiﬁc projects,
standardization constitutes a crucial methodological requirement,
because it enables systematized replication, assessment and vali-
dation of research ﬁndings across institutions, scientiﬁc commu-
nities and time. Barry (2006) has in this respect spoken of the
creation of “technological zones,”which he has deﬁned as “space[s]
within which differences between technical practices, procedures
and forms have been reduced, or common standards have been
established” (Barry, 2006: 239). While Barry recognizes that the
establishment of such technological zones is contested and char-
acterized by variation and changes over time, the concept implies
that a shared standard has become the guiding norm, and is
resulting in a reduction of differences between conﬂicting socio-
technological practices.
In emerging technology ﬁelds, such as regenerative stem cell
medicine, where state regulations are still evolvingdand interna-
tionally harmonized regulatory frameworks are not yet in place, a
more complex situation exists however. The case study of the China
SCI Net indicates in this respect, that due to the high level of reg-
ulatory diversity in the stem cell ﬁeld across (and also within)
countries, the enactment of internationally recognized research
standards in multi-country stem cell trials is a highly situation-
speciﬁc achievement. Internationally approved clinical research
protocols are established against a background of geographic,
institutional, epistemic-cultural and regulatory heterogeneity, and
implemented exclusively in the situational context of the clinical
trials that the Network organizes. As shown in the previous section,
outside of the activities of the China SCI Net, we see that locally
evolved and newly adopted (i.e. internationally accepted) forms of
experimental clinical research practices exist side by side with each
other, often in the same medical institutions. If we conceive of the
China SCI Net as the formation of a technological zone, in the sense
Barry uses the term, it becomes clear that the existence of such
zones can be highly temporary, and depends upon its activation in
speciﬁc situational contexts. Standardized methodological norms
and work arrangements across Network-afﬁliated hospitals are
activated exclusively in the context of the Network's clinical trials;
outside the context of these trials, heterogeneous clinical practices
continue to exist.7 Only some of these trials were with cells or stem cells. Others were surgical
trials, comparing different techniques and operation times.
8 Interview Nr. 20, senior researcher, South East China, September 7, 2010.This situation-speciﬁc character of transnational technological
zones, in which established standards can lay dormant for a while,
and switched on and off in relation to contextual demands, has not
yet been systematically explored in the literature. The case study
of the China SCI Net indicates in this respect, that in medical in-
stitutions that take part in such evolving transnational in-
frastructures, the adoption of homogenized clinical research
standards may only be temporary and bound to participation in
speciﬁc projects. Forms of clinical experimentation that have his-
torically evolved in local institutions and more recently adopted
(i.e. internationally recognized) clinical research practices,
continue to exist side by side with each other. Researchers switch
back and forth between these divergent schemas, depending on
the purposes of their research, the partners they work with, the
geographic scale of research projects, the targeted territorial scope
of marketization, and the contrasting demands for regulatory re-
view and approval that result from these differences. This situa-
tion differs fundamentally from the oncology research
cooperatives described by Keating and Cambrosio (2011), where
the adoption of a centrally deﬁned set of research standards has
become a permanent and obligatory requirement, and possibilities
for clinical experimentation outside of the cooperative structure
have become impossible.
6. The continuance of localized forms of value production
A key point is that the coexistence of distinct modes of clinical
translation allows also for the production of multiple forms of
economic value, at the level of local medical institutions. Localized
forms of value creation, which would not be acceptable to drug
regulatory agencies overseas, continue to exist e aside to partici-
pation in the internationally approved, multi-country clinical
research trials organized by the China SCI Net. As mentioned
above, in a clinic in South China experimental treatments with
various cell types were offered to patients in the context of clinical
pilot studies, exterior to the hospital's involvement in the Net-
work's stem cell trials. These experimental treatments have been
offered to patients on a pay-to-participate schema. The intensive
rehabilitation program that is now part of the China SCI Net's
clinical trial protocols, was also developed in this hospital. While
the efﬁcacy of this experimental rehabilitation program shall be
determined in the context of the network's clinical trials in the
future, it is offered since 2012 in a private hospital in China on a
for-proﬁt basis, and advertised to domestic patients and to spinal
cord injury patients from overseas. Another example that reﬂects
the local forms of economic value production that have emerged
in some of the institutions afﬁliated to the China SCI Net, are the
experimental therapies of a clinical researcher from North China.
This physician has offered experimental cell treatments to
reportedly several thousands of patients, from more than eighty
countries' during the last years.9 This researcher did not, however,
actively participate in the China SCI Net's clinical trials, but due to
his long-standing experience he played an important advisory role
in the selection and development of the surgical and cell trans-
plantation procedures that were used in the Network's clinical
trials.
The existence of such localized forms of value creation, that have
emerged outside of the requirements of international standard
regimens, aside to participation in internationally approved trials
can also be observed in other international research projects in9 This information stems from an information website of the Neurological Center
in Jingdong Zhongmei Hospital. URL: http://www.nrrfr.com/E/iframe.asp (last
accessed 10.10.14.)
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between Neuralstem, a biotech company from the USA that de-
velops stem cell-based therapies for neurodegenerative disorders,
and a large military hospital in Beijing. Neuralstem has received
approval from the US FDA for Phase I and II stem cell trials for
amyotrophic lateral sclerosis (ALS). These studies have been con-
ducted in the USA since 2011. In December 2013 the company
launched also a Phase I/II trial for the treatment of ischemic stroke
in China. The trial is carried out in a well-known military hospital
for brain disorders in Beijing. According to Richard Garr, the CEO of
Neuralstem, the protocol of the China trial has been developed for
use in the USA at a later point. It is performed in line with GCP
standards, and based on the quality controls and protocols for
expansion that are required by the US FDA (Ellis, 2014). Of interest
is that, aside to taking part in this high-proﬁle international clinical
research project, the hospital in Beijing has for many years offered
experimental for-proﬁt stem cell treatments, through its Stem Cell
Therapy Centre. On its website the center advertises experimental
treatments for a broad range of neurodegenerative disorders, that
range from stroke, to cerebral palsy, to Parkinson's disease, Alz-
heimer's disease, spinal cord injury, and others.10 While reportedly
300 patients from various countries had been treated until 2011, in
recent years the hospital seems to have focused in particular on the
Chinese market for the treatment of cerebral palsy. These experi-
mental for-proﬁt stem cell treatments are widely advertized, both
on the hospital's Chinese website, and on external Chinese lan-
guage websites.11
These ﬁndings indicate, that the integration of local knowledge
institutions into a global research economy does not unavoidably
result in the shutting down of localized forms of value production,
as recently argued by sociologist Kean Birch (2012). As Birch
(2012) has pointed out, the incorporation of local institutions
and locally derived inventions into a standardized global knowl-
edge economy, is intrinsically accompanied by the closing of local
market opportunities and knowledge exchanges. Localized forms
of exchange and proﬁt generation, which have emerged in the
original context of knowledge production, are terminated, through
the mandatory use of international standards, uniﬁed research
methodologies, and the application of legal instruments such as
international intellectual property rights (IPR) and global trade
rules (Birch, 2012: 190). While Birch's argument may be valid in
more established research ﬁelds in the biosciences where large-
scale transnational corporations play a central role, and in coun-
tries in which comprehensive regulatory arrangements are in
place, in emerging ﬁelds of medicine research, a more diversiﬁed
situation exists.
The example of the China SCI Net has shown in this respect, that
localized forms of value creation in medical institutions, that do not
conform to the requirements of international scientiﬁc standard
regimens, continue to exist e aside to participation in interna-
tionally approved, multi-country clinical research projects. But the
coexistence of processes of clinical translation through the conduct
of systematic forms of clinical trials, and the provision of experi-
mental for-proﬁt stem cell therapies, have also been documented in
other medical institutions and companies in China (Chen, 2009;
Song, 2011), as well as India (Sleeboom-Faulkner and Patra, 2011).
As recently suggested by McMahon (2014), the provision of10 Website of Stem Cell Therapy Centre, Bayi Hospital; URL: http://www.81scc.
com/en/zxjs.asp.
11 The Chinese language website of the Bayi Hospital on which these experimental
stem cell treatments are advertised can be found here: URL: http://www.zznews.
cn/yst/jdft/920140708281730.html. This and other websites on which these ther-
apies are advertised, have an interactive live-chat-function, that allows interested
patients to get information on the treatment from hospital staff.unproven stem cell intervention has itself developed into a global
industry that is now provided to tens of thousands of patients and
generate signiﬁcant economic revenues.
Here, two issues deserve to be mentioned. The ﬁrst is that
participation of hospitals in international clinical research projects
may increase the level of legitimacy for the provision of locally
evolved experimental therapies. This, in turn, is likely to maximize
local forms of value creation, also if these treatments have not been
developed in accordance with internationally recognized clinical
research standards. The second point is that the integration of
hospitals into amulti-country clinical trial infrastructuremay foster
the adoption of an evidence-based medicine (EBM) research cul-
ture e also in the context of local research projects. In the case of
the China SCI Net, for example, several of the investigators with
whom I spoke had started to conduct randomized controlled trials,
including domestic multi-center studies, independently from the
China SCI Net. These researchers reported that, in the ﬁeld of spinal
cord injury research, the shift toward more systematic clinical trials
was driven in particular by discontent with the widespread avail-
ability of unproven for-proﬁt stem cell therapies in China, and
related concerns for patients.7. Local value and the violation of property rights
A point that is thematically related to the argument of this
article, albeit not central to it, is that possibilities for the contin-
uation of localized forms of value creation are also linked to cross-
national differences in the enforcement of intellectual property
rights (IPR). In India, China and other rapidly developing countries
the protection and enforcement of property rights is often prob-
lematic. In China and India, for example, a longstanding record of
IPR infringements exists, including in the production of medicines
(Brhlikova et al., 2011; Mackey and Liang, 2011). IPR infringements
are also an issue in the ﬁeld of regenerative stem cell medicine. For
instance, the umbilical cord blood mononuclear cell/Lithium
combination that is tested by the China SCI Net (and which has
been patented by Stemcyte, the sponsor of the UCB cells) was
experimentally applied by a clinical researcher in India even
before the initial Phase I trial of the China SCI Net in Hong Kong
had started, apparently without any legal consequences.12 Similar
forms of IPR infringements were also expected in China, provided
the tested treatment is proved to be safe and efﬁcient. Researchers
of the China SCI Net stated, that legal prosecution of hospitals in
China that would offer the combination of Lithium and UCB cells
from somewhere other than Stemcyte is very unlikely. These re-
searchers expected, that alternative UCB products would soon
surface in the Chinese market (Rosemann, 2013b). For a theori-
zation of processes of value creation in the global bioeconomy, the
implicit acceptance of property right violations is important,
because it refers to the proﬁt potential of informal and illegal
economic activities in the biotech sector. In this article, though, I
have pointed to something else. I have shown that in emerging
ﬁelds of medicine research, that are regulated in highly divergent
ways across geographical regions, locally evolved clinical research
and for-proﬁt practices can continue to existeeeparallel to the
integration of local institutions into a standardized global research
economy. In contrast to proﬁts generated from IPR infringements,
however, these localized forms of value creation usually do not
take place outside of existing legal structures, and could not be
prosecuted by international law.12 This was reported by the researcher who conducted these experiments, at a
conference in Taiwan in April 2010.
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This paper has illustrated that the heterogeneity of regulation,
clinical research methodologies, and forms of commercialization
that can be observed in the clinical stem cell ﬁeld at a global level
poses signiﬁcant challenges to the organization of intercontinental
clinical stem cell research projects. It has become clear, that the
establishment of standardized clinical research practices across this
level of diversity, is a highly situation-speciﬁc achievement. Inter-
nationally acceptable clinical research practices exist alongside a
broad range of locally evolved forms of clinical experimentation,
often in the same medical institution. As I have shown, this coex-
istence of divergent socio-epistemic practices has enabled also the
generation of multiple forms of economic value. I have suggested in
this regard that e in contrast to a recent argument of Birch e the
integration of local institutions into the global bioeconomy does not
necessarily result in the shutting down of localized forms of value
creation. The ﬁndings of this paper indicate, that the high level of
generalization that underlies Birch's analysis of present-day pro-
cesses of value creation in the global bioeconomy, leaves out some
fundamental issues.
A ﬁrst point is that in emerging ﬁelds of medicine research, such
as stem cell research, the key actors are often not transnational
corporations, as stated by Birch. In the ﬁeld of regenerative stem cell
medicine, large-scale pharmaceutical corporations have for many
years been hesitant to invest. Themain advances, and forms of proﬁt
making that have evolved in recent years, were made by small to
mid-size biotech companies, usually in conjunction with academic
institutions. In countries where clinical stem cell applications have
been regulated at a low level, moreover, lucrative business oppor-
tunities have been exploited by private clinics, local investors, and
even individual physicians (Rosemann, 2013a; McMahon, 2014).
This suggests, that e in order to get a more nuanced picture of
contemporary processes of value production in the biomedical sci-
encese it is necessary to depart from amore nuanced analysis of the
different types of stakeholders that interact in the context of speciﬁc
subﬁelds of the biomedical sciences. The second point concerns the
need to take into account variation in terms of geographic and
regulatory location. In both, China and India state agencies have
taken for many years now a very reluctant position in adopting
stringent regulatory frameworks for clinical stem cell applications,
and to harmonize regulations with those issued in the USA and
European Union. In my ﬁeldwork in China in 2009 and 2010 various
policy makers expressed fears that the adoption of procedures as
handled by the US Food and Drug Administration, might suffocate
local innovation and market opportunities in the stem cell ﬁeld in
China. Minimal regulatory intervention, from this perspective, may
form a conscious political strategy to endorse localized forms of
value creation, at least up to the point at which more proﬁtable,
exportable products have been developed (Sleeboom-Faulkner,
2014). These geographically-based differences in policy positions,
and their implications for processes of innovation and market ex-
change, must be clearly understood in a theory of value creation of
the global bioeconomy. State agencies, as this example suggests, are
not always complicit in adopting (or enforcing) internationally
harmonized regulatory frameworks that prioritize global forms of
exchange, above policy options that prioritize more localized forms
of market activity. Third, geographic variation in the enforcement of
international IPR agreements is another crucial factor that must be
taken into account to fully comprehend the divergent ways inwhich
economic value is created in the global biomedical economy. The
implicit acceptance of property rights infringements in many
countries refers also to the huge ﬁnancial potential that the pro-
duction of counterfeit medicines, and in the future probably soon e
alternative stem cell products e generate.Acknowledgments
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